Fig. 3
From: The CD112R/CD112 axis: a breakthrough in cancer immunotherapy
CD112/CD155 and CD226/TIGIT/CD112R/CD96 pathway: CD226, TIGIT, CD112R, and CD96 on T and NK cells bound with their ligands CD112 and CD155 on tumor cells with different affinity. Upon binding, residues in cytoplasmic tails of CD226, CD112R, TIGIT, and CD96 were phosphorylated and produced co-stimulatory or co-inhibitory signals. (reviewed elsewhere [55])